Finerenone Compared With Placebo in Heart Failure Patients
Tests finerenone against placebo in adults with reduced-ejection-fraction heart failure who cannot take steroidal drugs.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
Key facts
- Where
- Akron, Aurora, Austin, Baton Rouge, Bradenton, Burlington, Centerville, Charlotte, Chula Vista, Cincinnati, Cynthiana, Denison, Fairhope, Greenville, Hammond, Hialeah, Houston, Jacksonville, Kansas City, Layton, Lexington, Louisville, Merrillville, Miami, Milwaukee, Minneapolis, Miramar, Norfolk, Northridge, Orange, Orangeburg, Paducah, Peoria, Phoenix, Pomona, Richmond, Sacramento, Salem, San Diego, San Francisco, Sherman Oaks, Tarzana, Tyler, Van Nuys, West Covina, West Hills, West Monroe, and Yuma, United StatesSee the 54 sites
- Phase
- Phase 3
Where in United States
- FIN-10081, Akron, OHAkron, United StatesTaking people
- FIN-10001, Aurora, COAurora, United StatesTaking people
- FIN-10110, Aurora, COAurora, United StatesTaking people
- AustinAustin, United StatesTaking people
- FIN-10030, Baton Rouge, LABaton Rouge, United StatesTaking people
- Bradenton, FL Investigative Site FIN-10125Bradenton, United StatesTaking people
- FIN-10053, Burlington, VTBurlington, United StatesTaking people
- FIN-10119, Centerville, OHCenterville, United StatesTaking people
- FIN-10318, Charlotte, NCCharlotte, United StatesTaking people
- Chula Vista, CA Investigative Site FIN-10111Chula Vista, United StatesTaking people
- Chula Vista, CA Investigative Site FIN-10419Chula Vista, United StatesTaking people
- FIN- 10112, Cincinnati, OHCincinnati, United StatesTaking people
- Cynthiana, KY Investigative Site FIN-10124Cynthiana, United StatesTaking people
- FIN-10404, Denison, TXDenison, United StatesTaking people
- FairhopeFairhope, United StatesTaking people
- Greenville, NC Investigative Site FIN-10122Greenville, United StatesTaking people
- FIN-10106, Hammond, LAHammond, United StatesTaking people
- FIN-10104, Hialeah, FLHialeah, United StatesTaking people
- FIN-10085, Houston, TXHouston, United StatesTaking people
- FIN-10028, Jacksonville, FLJacksonville, United StatesTaking people
- Kansas CityKansas City, United StatesTaking people
- FIN-10405, Layton, UTLayton, United StatesTaking people
- FIN-10080, Lexington, KYLexington, United StatesTaking people
- Lexington, KY Investigative Site FIN-10118Lexington, United StatesTaking people
- FIN-10086, Louisville, KYLouisville, United StatesTaking people
- Louisville, KY Investigative Site FIN-10417Louisville, United StatesTaking people
- FIN-10064, Merrillville, INMerrillville, United StatesTaking people
- FIN-10105, Miami, FLMiami, United StatesTaking people
- Milwaukee, WI Investigative Site FIN-10428Milwaukee, United StatesTaking people
- Minneapolis, MN Investigative Site FIN-10035Minneapolis, United StatesTaking people
- FIN-10113, Miramar, FLMiramar, United StatesTaking people
- FIN-10402, Norfolk, VANorfolk, United StatesTaking people
- FIN-10407, Northridge, CANorthridge, United StatesTaking people
- FIN-10412, Orange, CAOrange, United StatesTaking people
- Orangeburg, SC Investigative Site FIN-10433Orangeburg, United StatesTaking people
- FIN-10079, Paducah, KYPaducah, United StatesTaking people
- FIN-10019, Peoria, ILPeoria, United StatesTaking people
- Phoenix, AZ Investigative Site FIN-10115Phoenix, United StatesTaking people
- FIN-10070, Pamona, CAPomona, United StatesTaking people
- FIN-10093, Richmond, VARichmond, United StatesTaking people
- FIN-10024, Sacramento, CASacramento, United StatesTaking people
- Salem, VA Investigative Site FIN-10048Salem, United StatesTaking people
- San DiegoSan Diego, United StatesTaking people
- FIN-10406, San Diego, CASan Diego, United StatesTaking people
- San Diego, CA Investigative Site FIN-10420San Diego, United StatesTaking people
- San Francisco, CA Investigative Site FIN-10023San Francisco, United StatesTaking people
- FIN-10423, Sherman Oaks, CASherman Oaks, United StatesTaking people
- FON-10409, Tarzana, CATarzana, United StatesTaking people
- Tyler, TX Investigative Site FIN-10422Tyler, United StatesTaking people
- FIN-10109, Van Nuys, CAVan Nuys, United StatesTaking people
- FIN-10408, West Covina, CAWest Covina, United StatesTaking people
- FIN-10013, West Hills, CAWest Hills, United StatesTaking people
- FIN-10090, West Monroe, LAWest Monroe, United StatesTaking people
- FIN-10401, Yuma, AZYuma, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Colorado Prevention Center
- Trial code
- NCT06033950
- Record updated
- 10 July 2026
- Original description
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).Read full original descriptionShow less
A Randomized, Double-blind, Placebo-controlled Pragmatic Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure and Reduced Ejection Fraction Who Are Intolerant of or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF)
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).
Inclusion: Provide electronic or written informed consent, either personally or through a legally authorized representative, as permitted by local regulations; Age ≥18 years or legal age of majority if >18 years in the participant's country of residence; Symptomatic HFrEF per protocol defined criteria; Not on sMRA due to history of intolerance, contraindication, or ineligibility for treatment; Negative pregnancy test and agreement to use adequate contraception during trial (female participants only).
Exclusion: Treatment with non-steroidal MRA (nsMRA); Documented prior history of severe hyperkalemia in the setting of MRA use; Prior or planned heart transplant; Concomitant systemic therapy with potent cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors, or moderate or potent CYP3A4 inducers; Concurrent or previous participation in another interventional clinical study using an investigational agent within 30 days prior to randomization; Acute myocardial infarction, coronary revascularization, valve replacement/repair, or implantation of a cardiac resynchronization therapy device within 30 days or planned; Hemodynamically significant (severe) uncorrected primary cardiac valvular disease considered by the investigator to be the primary cause of heart failure; Symptomatic bradycardia or second- or third-degree heart block without a pacemaker; Cardiomyopathy due to known acute inflammatory heart disease, infiltrative diseases, accumulation diseases, muscular dystrophies, cardiomyopathy with reversible causes, hypertrophic obstructive cardiomyopathy, complex congenital heart disease, or pericardial constriction; Known hypersensitivity to the IP (active substance or excipients); Any other condition or therapy which would make the participant unsuitable for the study; eGFR < 25 mL/min/1.73m² and / or potassium > 5.0 mmol/L; Probable alternative cause of participant's HF.